Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Blue Cross Blue Shield of Michigan GLP-1 Coverage Changes Explained Understanding the New Coverage Changes As of August 1, 2024, Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network (BCN) are altering their coverage for GLP-1 receptor agonists, which include popular weight loss medications like Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)
Comprehensive documentation of batch information, storage conditions, assay setup, and handling procedures is recommended to support traceability, reproducibility, and cross-validation of results, especially in multi-site or collaborative research environments
Thank you VitalityMD for offering these innovative solutions
Conclusions Tirzepatide treatment was associated with improved self-reported HRQoL outcomes compared with placebo among people with obesity or overweight with T2D
Ozempic and Wegovy are registered trademarks of Novo Nordisk, A/S.
